- Home
- EXFY vs VSTM Comparison
EXFY vs VSTM Comparison
Compare EXFY & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- VSTM
- Stock Information
- Founded
- EXFY 2008
- VSTM 2010
- Country
- EXFY United States
- VSTM United States
- Employees
- EXFY N/A
- VSTM N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- VSTM Health Care
- Exchange
- EXFY Nasdaq
- VSTM Nasdaq
- Market Cap
- EXFY 309.9M
- VSTM 313.1M
- IPO Year
- EXFY 2021
- VSTM 2012
- Fundamental
- Price
- EXFY $3.04
- VSTM $6.08
- Analyst Decision
- EXFY Buy
- VSTM Strong Buy
- Analyst Count
- EXFY 4
- VSTM 8
- Target Price
- EXFY $5.00
- VSTM $13.00
- AVG Volume (30 Days)
- EXFY 416.1K
- VSTM 988.6K
- Earning Date
- EXFY 05-08-2025
- VSTM 03-20-2025
- Dividend Yield
- EXFY N/A
- VSTM N/A
- EPS Growth
- EXFY N/A
- VSTM N/A
- EPS
- EXFY N/A
- VSTM N/A
- Revenue
- EXFY $139,236,000.00
- VSTM $10,000,000.00
- Revenue This Year
- EXFY $9.33
- VSTM N/A
- Revenue Next Year
- EXFY $5.54
- VSTM $867.23
- P/E Ratio
- EXFY N/A
- VSTM N/A
- Revenue Growth
- EXFY N/A
- VSTM N/A
- 52 Week Low
- EXFY $1.24
- VSTM $2.10
- 52 Week High
- EXFY $4.13
- VSTM $13.52
- Technical
- Relative Strength Index (RSI)
- EXFY 38.28
- VSTM 42.16
- Support Level
- EXFY $3.20
- VSTM $6.01
- Resistance Level
- EXFY $3.60
- VSTM $6.89
- Average True Range (ATR)
- EXFY 0.18
- VSTM 0.47
- MACD
- EXFY -0.03
- VSTM -0.14
- Stochastic Oscillator
- EXFY 9.68
- VSTM 11.83
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.